We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. After a COPD exacerbation, patients face a raised risk ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

For patients with chronic obstructive pulmonary disease (COPD), bisoprolol does not reduce the number of self-reported exacerbations treated with oral corticosteroids, antibiotics, or both, according ...

Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage to the airways. It typically refers to emphysema and chronic bronchitis.

Surya Bhatt, MD, MSPH, of the University of Alabama at Birmingham, explained the phase 3 BOREAS and NOTUS trials demonstrated comparable safety profiles for dupilumab in treating patients with chronic ...

“I live with COPD, and I have experienced the emotional and physical toll it takes. Sadly, the status quo is unacceptable. We sorely need improved and new therapeutic approaches that will enable us to ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

SAN DIEGO -- The beta-blocker bisoprolol did not improve exacerbations in chronic obstructive pulmonary disease (COPD) patients, a randomized clinical trial found. Exacerbations requiring antibiotics, ...

About The Study: Among people with chronic obstructive pulmonary disease (COPD) at high risk of exacerbation, treatment with the β1-selective β-blocker bisoprolol did not reduce the number of ...